923289-30-9

Basic information

• Product Name: Ethanone,1-(2-amino-3-bromo-4-methoxyphenyl)-
• Synonyms: Ethanone,1-(2-amino-3-bromo-4-methoxyphenyl)-;1-(2-Amino-3-bromo-4-methoxyphenyl)ethanone;thanone,1-(2-aMino-3-broMo-4-Methoxyphenyl)-;1-(2-amino-3-bromo-4-methoxyphenyl)ethan-1-one
• CAS NO: 923289-30-9
• Molecular Formula: C₉H₁₀BrNO₂
• Molecular Weight: 244.09
• EINECS: 920-420-6
• Mol File: 923289-30-9.mol

Chemical Properties

• Boiling Point: 367.6±42.0 °C(Predicted)
• Appearance: /
• Density: 1.493±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -0.18±0.10(Predicted)
• CAS DataBase Reference: Ethanone,1-(2-amino-3-bromo-4-methoxyphenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone,1-(2-amino-3-bromo-4-methoxyphenyl)-(923289-30-9)
• EPA Substance Registry System: Ethanone,1-(2-amino-3-bromo-4-methoxyphenyl)-(923289-30-9)

Safety Data

• Hazardous Substances Data: 923289-30-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Ethanone,1-(2-amino-3-bromo-4-methoxyphenyl)is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Chemical Industry:
In the chemical industry, Ethanone,1-(2-amino-3-bromo-4-methoxyphenyl)serves as a key intermediate in the production of a wide range of organic compounds. Its versatility in organic synthesis makes it a valuable component in the creation of new chemical entities.
Used in Antibacterial Applications:
Ethanone,1-(2-amino-3-bromo-4-methoxyphenyl)has been studied for its potential antibacterial properties. Its unique structure may contribute to its ability to inhibit the growth of certain bacteria, making it a promising candidate for the development of new antimicrobial agents.
Used in Anticancer Applications:
Research has also explored the potential anticancer properties of Ethanone,1-(2-amino-3-bromo-4-methoxyphenyl)-. Its unique structure may allow it to target and inhibit the growth of cancer cells, offering a new avenue for cancer treatment and research.
Overall, Ethanone,1-(2-amino-3-bromo-4-methoxyphenyl)is a versatile chemical with a range of potential applications in research and industry, from pharmaceutical and chemical synthesis to antibacterial and anticancer therapies. Its unique structure and properties make it a valuable compound for further exploration and development.

Upstream product

• 112970-44-2 2-bromo-3-methoxyaniline 
• 75-05-8 acetonitrile 
• 67853-38-7 2-bromo-3-methoxyphenylamine hydrochloride 

Downstream Products

• 923289-31-0 C₁₃H₁₁BrN₂O₃S 
• 1245553-60-9 N-(6-acetyl-2-bromo-3-methoxyphenyl)-2-(isopropylamino)-thiazole-4-carboxamide 
• 1219105-45-9 C₁₇H₁₈BrN₃O₄S 
• 1108658-98-5 N-(6-acetyl-2-bromo-3-methoxyphenyl)-4-isopropylthiazole-2-carboxamide 

Relevant articles and documents

CRYSTALLINE FORMS OF A 2-THIAZOLYL- 4-QUINOLINYL-OXY DERIVATIVE, A POTENT HCV INHIBITOR

This invention relates to novel crystalline forms of the following Compound (1), and the sodium salt thereof, and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection.

MACROCYCLIC SERINE PROTEASE INHIBITORS

Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula I, pharmaceutical compositions comprising such compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors

Starting from the previously reported HCV NS3/4A protease inhibitor BILN 2061 (1), we have used a fast-follower approach to identify a novel series of HCV NS3/4A protease inhibitors in which (i) the P3 amino moiety and its capping group have been truncated, (ii) a sulfonamide is introduced in the P1 cyclopropyl amino acid, (iii) the position 8 of the quinoline is substituted with a methyl or halo group, and (iv) the ring size of the macrocycle has been reduced to 14 atoms. SAR analysis performed with a limited set of compounds led to the identification of N-{17-[8-chloro-2-(4-isopropylthiazol-2-yl)-7-methoxyquinolin-4-yloxy]-2,14-dioxo-3,15-diazatricyclo [13.3.0.0 [Bartenschlager, R.; Lohmann, V. J. Gen. Virol. 2000, 81, 1631; Vincent Soriano, Antonio Madejon, Eugenia Vispo, Pablo Labarga, Javier Garcia-Samaniego, Luz Martin-Carbonero, Julie Sheldon, Marcelle Bottecchia, Paula Tuma, Pablo Barreiro Expert Opin. Emerg. Drugs, 2008, 13, 1-19]]octadec-7-ene-4-carbonyl}(1-methylcyclopropyl)(1-methylcyclopropyl)sulfonamide 19l an extremely potent (Ki = 0.20 nM, EC50 = 3.7 nM), selective, and orally bioavailable dipeptide NS3/4A protease inhibitor, which has features attractive for further preclinical development.

MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS

Inhibitors of HCV of formula (I), and the N-oxides, salts, and stereochemically isomeric forms thereof, wherein R1 is aryl or a saturated, a partially unsaturated or completely unsaturated 5 or 6 membered monocyclic or 8 to 12 membered bicyclic heterocyclic ring system containing one nitrogen, and optionally one to three oxygen, sulfur or nitrogen, wherein said ring system may be optionally substituted; L is a direct bond, -O-. -O-C1-4alkanediyl-, -O-CO-, -O-C(=O)-NR5a- or -O-C(=O)-NR5a-C1-4alkanediyl-; R2 is hydrogen, -OR6, -C(O)OR6, -C(=O)R7, -C(=O)NR5aR5b, -C(=O)NHR5c, -NR5aR5b, -NHR5c, -NHSOpNR5aR5b, -NR5aSOpR8, or -B(OR6)2; R3 and R4 are hydrogen or C1-6alkyl; or R3 and R4 taken together may form a C3-7cycloalkyl ring; n is 3, 4, 5, or 6; p is 1 or 2; aryl is phenyl, naphthyl, indanyl, or 1,2,3,4-tetrahydronaphthyl, each of which may be optionally substituted Het is a 5 or 6 membered saturated, partially unsaturated or completely unsaturated heterocyclic ring containing 1 to 4 heteroatoms each independently selected from nitrogen, oxygen and sulfur, being optionally condensed with a benzene ring, and wherein the group Het as a whole may be optionally substituted ; pharmaceutical compositions containing compounds (I) and processes for preparing compounds (I). Bioavailable combinations of the inhibitors of HCV of formula (I) with ritonavir are also provided.